A concise update on how AI is accelerating drug discovery, from structure prediction to trial optimization, with industry examples and next steps.
How AI Is Reshaping Drug Discovery: Speed, Precision, and What Comes Next Read More »
Concise update on how AI speeds target identification, lead design, virtual screening and clinical trials, and what this means for precision medicine and pharma R&D.
How AI Is Reshaping Drug Discovery: Speed, Precision, and Risk Reduction Read More »
How AI and tech capital are shifting drug discovery to a fail-fast model, de-risking early R&D while creating investor tensions and strategic tradeoffs.
AI and the ‘Fail-Fast’ Revolution in Drug Discovery Read More »
Recursion and Genentech report the first validated neuroscience target found by AI. Learn how CRISPR, cellular imaging and supercomputing made it possible and what comes next.
Recursion and Genentech Validate First AI-Discovered Neuroscience Target Read More »
A concise expert view on AI in drug discovery: how ML evolved into GenAI, key barriers like workflow integration and LLM costs, and practical steps for researchers.
AI in Drug Discovery: Hype, Practical Limits and First Steps for Scientists Read More »
Verseon’s physics-first Deep Quantum Modeling designs novel drug chemistries beyond AI training limits, creating candidates for lower-bleeding anticoagulants and diabetic eye disease.
Physics-First Drug Design: How Verseon Builds New Medicines Beyond AI Training Data Read More »
Explore how AI is transforming drug discovery — from target ID to smarter clinical trials — cutting time and cost while improving patient outcomes. A concise outlook for healthcare leaders and investors.
AI Drug Discovery: How Machine Learning Is Speeding Up New Medicines Read More »
A concise, realistic guide to where AI adds measurable value in drug discovery: data enrichment, experiment prioritization, and multi-parameter optimization. Practical limits and steps for teams.
AI in Drug Discovery: Practical Value, Not Hype Read More »
How generative AI and protein structure prediction are shortening drug discovery timelines, with examples, practical impacts, and strategic considerations for pharma leaders.
Generative AI Meets Structure Prediction: Faster Drug Discovery for Pharma R&D Read More »
How Insilico Medicine’s Pharma.AI fuses foundation models, AI agents, Generative Biologics, Chemistry42, PandaClaw and MMAI Gym to speed drug discovery.
